A New Standard for Starting Material Quality
Cell banks are the foundation of every advanced biologic and ATMP program — and a crucial anchor for biomanufacturing performance and PAT‑driven process control. The same is true for all cellular starting material, including donor‑derived and patient‑derived cells, where early quality signals directly influence downstream success. Variability in starting material can ripple through development, scale‑up, and manufacturing — affecting productivity, potency, yields, and overall product quality. Yet traditional characterization methods often rely on slow, label-based methods and low‑resolution assays that miss early indicators of cell health and functional performance.
Radiance® changes this. Built on Laser Force Cytology™ (LFC), Radiance® delivers label‑free, single‑cell measurements that quantify intrinsic biochemical and biophysical properties in real time. Because LFC measures the entire cell — capturing a holistic, unmodified view of its intrinsic properties — these signatures reflect true cellular function across cell banks, donor material, and patient-derived starting cells. They also provide early, predictive indicators of how starting material will perform later in the process. Teams gain a clearer, earlier understanding of cellular quality, enabling more confident decisions from early development through commercial manufacturing.
Speak To An Expert
Why Cell Bank Characterization Matters
Cell banks must be consistent, stable, and predictive of downstream performance. The same expectations apply to allogenic donor material, where functional variability can significantly impact ATMP development and manufacturing outcomes. Because cell banks set the trajectory for upstream and downstream performance, they are a critical control point in biomanufacturing and PAT frameworks, where early, high‑resolution analytics are essential for improved process understanding and control.
Current industry standards present many challenges:
- Label‑dependent assays introduce artifacts and delay results
- Bulk measurements mask population heterogeneity
- Slow turnaround times limit rapid decision‑making
- Limited sensitivity makes it difficult to detect subtle shifts in cell health
- Inconsistent methods complicate comparability and regulatory alignment
As regulatory expectations around potency, CMC rigor, and analytical robustness continue to increase, developers need tools that can deliver quantitative, mechanism‑relevant insights into all forms of starting material — not just basic viability checks. They need analytics capable of forecasting how starting material will behave under process stress, cryopreservation, or scale‑up conditions, and supporting more confident, data‑driven decisions.
How Radiance® Takes Cellular Qualification to the Next Level
Radiance® delivers a direct, label‑free readout of true cellular function, giving teams the resolution and speed needed to qualify starting material with far greater confidence. With whole‑cell, single‑cell precision, Radiance® enables teams to:
- Detect early, subtle phenotypic, biochemical, and biophysical shifts that influence downstream performance long before traditional assays respond.
- Compare cell banks, donor lots, and patient‑derived material with high‑resolution, single‑cell clarity to uncover meaningful differences in quality.
- Strengthen comparability and tech transfer using quantitative datasets that support consistent decision‑making across sites and programs.
- Reduce risk during scale‑up and manufacturing by identifying functional decline or stress signatures earlier in the workflow.
- Predict downstream performance by resolving functional signatures linked to potency, viability loss, and stress response.
By capturing holistic, intrinsic whole‑cell signatures without fluorescent labels or genetic reporters, Radiance® provides an unmodified, highly sensitive view of starting‑material quality — delivered in minutes, not days. These insights power PAT‑aligned monitoring strategies with real‑time, single‑cell measurements that reflect the cell’s true functional state.
Speak To A Laser Force Cytology Expert
Predictive Insights for Better Process Control
Radiance® provides rapid, label‑free visibility into cell health and functional readiness, enabling teams to detect meaningful changes in starting material long before they affect process performance. With whole‑cell, single‑cell sensitivity, Radiance® resolves early shifts that traditional assays routinely miss.
In one study, Vero cells frozen using different methods were compared to a standard reference protocol and analyzed immediately post‑thaw. Cells frozen without DMSO or subjected to rapid, uncontrolled freezing showed a pronounced drop in the Radiance® Optical Force Index — a clear indicator of compromised post‑thaw fitness and reduced functional potential.
Crucially, LFC signatures collected before cryopreservation predicted which samples were most likely to lose potency during freezing, demonstrating Radiance®’s ability to identify at‑risk starting material before it enters production. This early insight empowers teams to intervene sooner, protect downstream performance, and avoid costly failures.
By shifting from retrospective checks to forward‑looking functional analytics, Radiance® transforms starting‑material monitoring into a proactive, predictive quality‑control strategy.
Standard/Same as Reference
High FBS Concentration
No DMSO
Uncontrolled Freezing
Strengthening Regulatory Alignment From the Very Start
Regulators, including the FDA, increasingly expect quantitative, mechanism‑relevant analytics to support potency, CMC rigor, and lifecycle control. Radiance® provides the high‑resolution, reproducible single‑cell data needed to:
- Demonstrate predictive understanding of how starting material influences downstream quality
- Support potency‑linked assessments
- Strengthen comparability across banks, lots, donors, and patient samples
- Build more defensible data packages
- Reduce friction during tech transfer
- Improve confidence in regulatory submissions
By integrating Radiance® early, teams establish a stronger analytical foundation that supports smoother development and more predictable outcomes. These predictive, mechanism‑relevant insights align with FDA expectations around enhanced process understanding and implementing PAT‑enabled control strategies.
A More Confident Path Forward
Starting‑material quality defines the trajectory of every advanced biologic and ATMP program. Whether sourced from a cell bank, donor, or patient, its functional strength determines how reliably a process will scale, how consistently it will perform, and how confidently it will meet regulatory expectations.
Radiance® gives developers the clarity, speed, and predictive power needed to qualify starting material with far greater certainty. By resolving whole‑cell functional signatures in real time, Radiance® helps teams move faster, reduce variability, and build more resilient, higher‑quality processes from the very first step.
It all begins with the cell — and Radiance® ensures you start with the strongest foundation possible.
